Economic analysis of newer antiepileptic drugs.
Authors:
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 22 (10) , 861-875
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- ILAE Treatment Guidelines: Evidence‐based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and SyndromesEpilepsia, 2006
- Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision ModelMedical Decision Making, 2005
- Economic Evaluation of Levetiracetam as an Add-On Therapy in Patients with Refractory EpilepsyPharmacoEconomics, 2005
- Direct Cost of Medical Management of Epilepsy among Adults in Italy: A Prospective Cost‐of‐Illness Study (EPICOS)Epilepsia, 2004
- A Markov model of treatment of newly diagnosed epilepsy in the UKThe European Journal of Health Economics, 2003
- The Cost Effectiveness of Two New Antiepileptic Therapies in the Absence of Direct Comparative DataPharmacoEconomics, 2003
- Cost Minimization Analysis of Antiepileptic Drugs in Newly Diagnosed Epilepsy in 12 European CountriesEpilepsia, 2000
- Cost of Epilepsy in the United States: A Model Based on Incidence and PrognosisEpilepsia, 1994